Carl Zeiss Meditec Group
Dr. Markus Weber, President and CEO
Justus Felix Wehmer, CFO
Aug 4, 2023
Agenda
01 9M 2022/23 at a Glance
02 Financial Performance
03 Highlights
04 Outlook
Carl Zeiss Meditec Group | Page 2 |
Strong revenue growth in 9M 2022/23 with continued high order backlog Ongoing strategic investment leads to reduced EBIT
9M 2022/23
9M 2021/22
9M 2022/23
9M 2021/22
9M 2022/23
9M 2021/22
Revenue | |
€ 1,509.6 million | FX-adj. revenue growth of +12.9% |
Positive revenue trend in both SBUs and all regions despite continuing supply chain | |
+13.3% | |
constraints and macroeconomic challenges | |
1,332.9 | |
Open orders of € 537m still at elevated levels | |
EBIT | |
€ 244.9 million | EBIT margin at 16.2% (PY 20.7%) |
Sequential gross margin improvement from Q1 through Q3 mainly due to recovery in | |
-11.2% | |
consumables business, Q3 gross profit and EBIT above PY's level | |
275.9 | |
Higher OpEx mainly arising from strategic investments in S&M and R&D for growth and | |
innovation initiatives | |
Adj. EBIT margin at 16.8% (PY 21.2%) | |
EPS | |
€ 2.29 | Higher earnings per share due to positive contribution from interest income, FX hedging |
+7.3% | |
2.14 |
Carl Zeiss Meditec Group | Page 3 |
Agenda
01 9M 2022/23 at a Glance
02 Financial Performance
03 Highlights
04 Outlook
Carl Zeiss Meditec Group | Page 4 |
Ophthalmology
Topline growth primarily driven by accelerating deliveries of devices
Revenue
9M 2022/23 | € 1,152.3 million FX-adj. revenue growth of +11.8% | |||
+12.2% | Delivery of devices accelerated towards end of period - VISUMAX lead times still elevated | |||
9M 2021/22 | 1,027.2 | Refractive treatment packs below PY's high levels (inventory build in China in H2 21/22) | ||
9M 2022/23
9M 2021/22
EBIT margin | ||
14.0% | EBIT margin decline affected by: | |
Weaker product mix due to slower consumables growth and supply | ||
-6.0 pps | − | |
20.0% | constraints in refractive business | |
− | Continued high level of strategic investment in research & development | |
and sales & marketing
MCS
Revenue Split
OPT | 76.3% |
of total revenue |
Carl Zeiss Meditec Group | Page 5 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Carl Zeiss Meditec AG published this content on 04 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2023 05:11:32 UTC.